Walgreens is wading into the self-pay GLP-1 space, going head-to-head with telehealth subscription offerings. The retail pharmacy giant launched a digital weight management service to offer access to ...

DAVIS, Calif.—The Connectivity Standards Alliance (CSA) has announced the release of the Aliro 1.0 specification, a new communication protocol and credential standard designed to revolutionize how ...

Monday - Friday, 6:00 - 7:00 PM ET In a Monday interview with CNBC's Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the pharmaceutical giant's new pill format of its weight loss drug will allow ...

Suzuki Motorcycle India has finally entered the electric two-wheeler segment with the launch of the Suzuki e-ACCESS, priced at Rs 1.88 lakh, ex-showroom. Bookings for the company’s first electric ...

Suzuki Motorcycle India has launched its first electric scooter in the Indian market called the e-Access. Introduced at Rs 1.88 lakh (ex-showroom), the electric two-wheeler will be manufactured at the ...

The Suzuki e-Access has a claimed range of just 95km on a single full charge. Suzuki starts bookings for its first electric scooter, e-Access, priced at Rs 1,88,490. e-Access has a 3.07kWh LFP battery ...

Suzuki has finally launched the e-Access electric scooter in India at a surprising price of Rs 1,88,490 (ex-showroom, Delhi). Bookings are now open across all authorised Suzuki dealerships in the ...

Suzuki has opened bookings for its first electric scooter, the Suzuki e-Access, marking the brand’s entry into the Indian electric two-wheeler market. We reviewed the e-Access early last year and the ...

Novo Nordisk Launches Daily Weight-Loss Pill to Expand GLP-1 Access TUESDAY, Jan. 6, 2026 (HealthDay News) — A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo Nordisk ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly ...

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...

As GLP-1 receptor agonists move into wider use for diabetes and weight management, many primary care clinicians are discovering that prescribing the medication is only half the challenge. The other ...